
Indicated for the treatment of foregut, midgut and hindgut neuroendocrine tumors, the radiopharmaceutical Bravnetsa is reportedly bioequivalent and therapeutically equivalent to the previously FDA-approved Lutathera.
COVER STORY
By: Clare Tempany, M.D., Jalil Afnan, M.D., and Nathan McDannold, PH.D.
DEPARTMENTS
Agenda
By: John C. Hayes
Overread
Newsclips
Diagnostic Imaging supplement
In Review: News from the RSNA Meeting
X-Ray Vision
Magnetic Resonance
Tech Watch
Ultrasound
Intervention
Practice Issues
Perturbations
over 17 years ago
When the RSNA throws the book at us, we read it allover 17 years ago
California blamesoperator errorfor CT incidentover 17 years ago
Is this radiology's best connected couple?over 17 years ago
Iso-osmolar agent showshigher renal failure rateover 17 years ago
CMS hesitates to approvePET for cancer despite dataover 17 years ago
Chest CT assists follow-upof head and neck cancerover 17 years ago
Economic woes affect attendanceover 17 years ago
Expertise with MSCT-CA takes timeover 17 years ago
Illegal patient info sneaks into PowerPoint filesover 17 years ago
Moolah getsreports flyingout the door



